Barclays Maintains Equal-Weight on Varonis Systems, Raises Price Target to $30

Barclays analyst Saket Kalia maintains Varonis Systems (NASDAQ:VRNS) with a Equal-Weight and raises the price target from $29 to $30.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Barclays analyst Saket Kalia maintains Varonis Systems (NASDAQ:VRNS) with a Equal-Weight and raises the price target from $29 to $30.

Barclays Maintains Overweight on GoodRx Holdings, Lowers Price Target to $8

By Benzinga Newsdesk

January 18, 9:05 AM

Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $9 to $8.

GDRX

Grove’s Acquisitions Fueling Company’s Growth

By Margaret Jackson

September 22, 10:18 AM

Since its initial public offering (IPO) in June, Grove Inc. (NASDAQ: GRVI) has embarked on a journey that will establish it as a leading manufacturer of hemp-derived CBD-based products as well as nutritional supplements.

ALF

If You Invested $1,000 In ChargePoint Stock One Year Ago, Here’s How Much You’d Have Now

By Wayne Duggan

September 28, 3:51 PM

Investors who have owned stocks in the last 12 months have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return since Sept. 28, 2020, is 34.7%. But there is no question some big-name stocks performed better than others along the way.

CHPT

Bright Minds’ Second-Gen Psychedelic Drugs Ready to Be Embraced by Investors, Big Pharma

By Ernest Dela Aglanu

July 26, 10:56 AM

Bright Minds Biosciences (OTC: BMBIF), a Canadian-based biotechnology company, is developing the next-generation serotonergic drugs to treat various central nervous system (CNS) disorders.

BMBIF

Barclays Maintains Equal-Weight on Varonis Systems, Raises Price Target to $30

Related Posts

Barclays Maintains Overweight on GoodRx Holdings, Lowers Price Target to $8

Grove’s Acquisitions Fueling Company’s Growth

If You Invested $1,000 In ChargePoint Stock One Year Ago, Here’s How Much You’d Have Now

Bright Minds’ Second-Gen Psychedelic Drugs Ready to Be Embraced by Investors, Big Pharma